Clopidogrel + ASA vs Placebo + ASA: Adjudicated Major Bleedings

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measure	Value	95% interval, lower	95% interval, upper	Method	Source
Risk in group 1	0.0665	0.059	0.0749	wilson	ClinicalTrials.gov
Risk in group 2	0.0428	0.0368	0.0498	wilson	ClinicalTrials.gov
Risk difference, group 1 minus group 2	0.0237	0.0135	0.034	newcombe hybrid score	ClinicalTrials.gov
Risk ratio, group 1 over group 2	1.55	1.28	1.88	log	ClinicalTrials.gov
Odds ratio, group 1 over group 2	1.59	1.3	1.95	log	ClinicalTrials.gov
Number needed to treat, for one more participant with the outcome on Clopidogrel + ASA than on Placebo + ASA	42.2	29.4	74.2	from the risk difference interval	ClinicalTrials.gov

Groups 2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

Group	Title	Description	With the outcome	Analysed	ClinicalTrials.gov code	Source
Group 1	Clopidogrel + ASA	Clopidogrel 75 mg once daily (od) plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)	251	3,772	OG000	ClinicalTrials.gov
Group 2	Placebo + ASA	Matching placebo of clopidogrel 75 mg od plus ASA 75 to 100 mg od recommended (dose at the investigators' discretion)	162	3,782	OG001	ClinicalTrials.gov

Outcome 5

Field	Value	Source
Type	SECONDARY	ClinicalTrials.gov
Title	Adjudicated Major Bleedings	ClinicalTrials.gov
Description	The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug).	ClinicalTrials.gov
Time frame	expected median follow-up of approximately 3 years	ClinicalTrials.gov
Population	The intent-to-treat (ITT) population was used for the analysis.	ClinicalTrials.gov

Trial 8

Field	Value	Source
Title	Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)	ClinicalTrials.gov
NCT number	NCT00249873	ClinicalTrials.gov
Phases	PHASE3	ClinicalTrials.gov
Conditions	Atrial Fibrillation, Vascular Risk	ClinicalTrials.gov
Interventions	clopidogrel (SR25990C), placebo	ClinicalTrials.gov
Lead sponsor	Sanofi	ClinicalTrials.gov
Results first posted	2010-03-26	ClinicalTrials.gov
Results on ClinicalTrials.gov	https://clinicaltrials.gov/study/NCT00249873?tab=results	ClinicalTrials.gov

Source 4

Field	Value	Source
Release	trial-comparisons-2026-03-23-0.1.0	ClinicalTrials.gov
Release manifest SHA-256	f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57	ClinicalTrials.gov
AACT copy	2026-03-23	ClinicalTrials.gov
Tables read	outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet	ClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.